Interferon in chronic myeloid leukaemia: past and future. - Archive ouverte HAL Access content directly
Journal Articles Bailliè re s Best Practice and Research in Clinical Haematology Year : 2009

Interferon in chronic myeloid leukaemia: past and future.

(1, 2) , (1, 2) , (1, 2) , (1, 2)
1
2

Abstract

Imatinib has revolutionized the therapy of chronic myeloid leukaemia. However the complete eradication of leukaemic stem cells is still a matter of discussion. Interferon (IFN) has been used in the past with success. However the proportion of patients who achieved sustained complete cytogenetic response was small. Recently, in addition to its direct antineoplastic effect and immunomodulatory activity, IFN has been shown to stimulate the quiescent leukaemic stem cells. Thus there is now a rational for combining Imatinib and IFN. Large prospective phase III trials are in good progress to demonstrate in humans the usefullness of a combination therapy using Imatinib and IFN.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-00441364 , version 1 (15-12-2009)

Identifiers

Cite

François Guilhot, Lydia Roy, Pierre-Jean Saulnier, Joëlle Guilhot. Interferon in chronic myeloid leukaemia: past and future.. Bailliè re s Best Practice and Research in Clinical Haematology, 2009, 22 (3), pp.315-29. ⟨10.1016/j.beha.2009.10.005⟩. ⟨inserm-00441364⟩
84 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More